Hesperos, Inc. (HESP)
Hesperos will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
| Market Cap | n/a |
| Revenue (ttm) | 5.11M |
| Net Income (ttm) | -773,316 |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About HESP
Hesperos, Inc. is a socially-conscious company that uses our non-invasive, serum-free, multi-organ chip platform (Human-on-a-Chip) systems to provide pre-clinical analytical services with the goal of accelerating drug discovery and general toxicology testing and reducing use of animal testing. Our Human-on-a-Chip platform system mimics the process of initial patient evaluation during a clinical trial, where functional human in vitro tissues are evaluated similar to a patient undergoing medical testing to determine baseline performance metrics. ... [Read more...]
Industry
Health Care
Founded
2015
CEO
James F. Kronauge, Jr., Ph.D.
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
HESP
Financial Performance
Financial StatementsNews
Hesperos IPO Registration Document (S-1)
Hesperos has filed to go public with an IPO on the NASDAQ.